<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369523</url>
  </required_header>
  <id_info>
    <org_study_id>74975</org_study_id>
    <nct_id>NCT02369523</nct_id>
  </id_info>
  <brief_title>Multimodal Pain Management Following Primary TKA</brief_title>
  <official_title>Periarticular Infusion With Liposomal Bupivacaine or a Ropivacaine Cocktail Versus Continuous Femoral Nerve Catheters for Multimodal Pain Management Following Primary TKA: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to evaluate the length of time to discharge readiness between the
      groups (continuous femoral nerve blocks (cFNB) vs. liposomal bupivacaine (LB) vs.
      periarticular infusion cocktails (PIC) following primary total knee arthroplasty (TKA). In
      addition, the investigators will compare quadriceps strength recovery over time and
      exploratory variables between the groups.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Adequate enrollment was not reached for this study.
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Discharge Readiness</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an average of 3 days</time_frame>
    <description>Time to discharge readiness will be defined as the time from surgical stop to the time of the 2nd consecutive assessment where all criteria are fulfilled.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>liposomal bupivacaine (LB) (Exparel)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mixture of 50 milliliters (mL) of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine cocktail (PIC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 milligrams (mg) Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>continuous femoral nerve blocks (cFNB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.
Sciatic nerve block - 0.125% bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.</description>
    <arm_group_label>liposomal bupivacaine (LB) (Exparel)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine cocktail (PIC)</intervention_name>
    <description>400 mg Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution</description>
    <arm_group_label>Ropivacaine cocktail (PIC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.
Sciatic nerve block - 0.125% bupivacaine</description>
    <arm_group_label>continuous femoral nerve blocks (cFNB)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 40 Years Old

          -  Scheduled for Primary Total Knee Arthroplasty

        Exclusion Criteria:

          -  Opiate Tolerant (≥60mg/day oral morphine/equivalent for ≥1 week)

          -  Neuromuscular deficit affecting the lower limbs

               -  Peripheral neuropathy

               -  Radiculopathy/Sciatica

          -  Known allergy or intolerance to Bupivacaine or Ropivacaine

          -  Hepatic Disease

          -  Renal Disease/Patients needing Dialysis

          -  Planned unicompartmental knee replacement

          -  Less than 90 degree of knee flexion preoperatively.

          -  Patients who lack the capacity to consent or are unwilling to do so

          -  At the discretion of the PI, patients who may have difficulty complying with standard
             of care (SOC) followup may also be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Pelt, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah Orthopaedic Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Christopher Pelt</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Primary Total Knee Arthroplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

